RT Journal Article
SR Electronic
T1 Favourable vaccine-induced SARS-CoV-2 specific T cell response profile in patients undergoing immune-modifying therapies
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.02.21.22271127
DO 10.1101/2022.02.21.22271127
A1 Qui, Martin
A1 Bert, Nina Le
A1 Chan, Webber Pak Wo
A1 Tan, Malcolm
A1 Hang, Shou Kit
A1 Hariharaputran, Smrithi
A1 Sim, Jean Xiang Ying
A1 Low, Jenny Guek Hong
A1 Ng, Wei Ling
A1 Wan, Wei Yee
A1 Ang, Tiing Leong
A1 Bertoletti, Antonio
A1 Salazar, Ennaliza
YR 2022
UL http://medrxiv.org/content/early/2022/02/23/2022.02.21.22271127.abstract
AB Patients undergoing immune-modifying therapies demonstrate a reduced humoral response after COVID-19 vaccination, but we lack a proper evaluation of the impact of such therapies on vaccine-induced T cell responses. Here, we longitudinally characterised humoral and Spike-specific T cell responses in inflammatory bowel disease (IBD) patients who are on antimetabolite therapy (azathioprine or methotrexate), TNF inhibitors and/or other biologic treatment (anti-integrin or anti-p40) after mRNA vaccination up to 3 months after completing two vaccine doses. We demonstrated that a Spike-specific T cell response is not only induced in treated IBD patients at levels similar to healthy individuals, but also sustained at higher magnitude, particularly in those treated with TNF inhibitor therapy. Furthermore, the Spike-specific T cell response in these patients is mainly preserved against mutations present in SARS-CoV-2 B.1.1.529 (Omicron) and characterized by a Th1/IL-10 cytokine profile. Thus, despite the humoral response defects, the favourable profile of vaccine-induced T cell responses might still provide a layer of COVID-19 protection to patients under immune-modifying therapies.Competing Interest StatementN. Le Bert and A. Bertoletti reported a patent for a method to monitor SARS-CoV-2-specific T cells in biological samples pending. The other authors have declared no competing interests.Funding StatementThis study was supported by funds under the NCID Catalyst Grant and administered by the National Centre for Infectious Diseases.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethic committee of Singapore General Hospital gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript